ZA961791B - Reduction of infarct volume using citicoline - Google Patents

Reduction of infarct volume using citicoline

Info

Publication number
ZA961791B
ZA961791B ZA961791A ZA961791A ZA961791B ZA 961791 B ZA961791 B ZA 961791B ZA 961791 A ZA961791 A ZA 961791A ZA 961791 A ZA961791 A ZA 961791A ZA 961791 B ZA961791 B ZA 961791B
Authority
ZA
South Africa
Prior art keywords
citicoline
reduction
infarct volume
infarct
volume
Prior art date
Application number
ZA961791A
Other languages
English (en)
Inventor
Bobby W Sandage Jr
Marc Fischer
Kenneth W Locke
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23578854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA961791(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Publication of ZA961791B publication Critical patent/ZA961791B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA961791A 1995-03-06 1996-03-05 Reduction of infarct volume using citicoline ZA961791B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39926295A 1995-03-06 1995-03-06

Publications (1)

Publication Number Publication Date
ZA961791B true ZA961791B (en) 1996-09-10

Family

ID=23578854

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961791A ZA961791B (en) 1995-03-06 1996-03-05 Reduction of infarct volume using citicoline

Country Status (5)

Country Link
US (2) US5872108A (cs)
KR (1) KR19980702724A (cs)
IL (1) IL147477A (cs)
IN (1) IN182555B (cs)
ZA (1) ZA961791B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6732369B1 (en) * 1995-10-02 2004-05-04 Starsight Telecast, Inc. Systems and methods for contextually linking television program information
JP4530534B2 (ja) * 1997-12-24 2010-08-25 フエルレル インターナショナル、ソシエダッド アノニマ 超水和シチコリン、プロセスおよび使用
US6379882B1 (en) * 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
AU2001247759A1 (en) * 2000-03-24 2001-10-08 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
WO2003100570A2 (en) * 2002-05-23 2003-12-04 New England Medical Center Hospitals, Inc. Computer-assisted multi-dimensional patient selection
CA2566612C (en) * 2004-05-13 2015-06-30 Massachusetts Institute Of Technology Uridine effects on dopamine release
SI1888059T1 (sl) 2005-06-01 2015-05-29 Edison Pharmaceuticals, Inc. Redoks-aktivni terapevtiki za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznaäśevalcev
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP2470168B1 (en) 2009-08-26 2018-01-31 BioElectron Technology Corporation Methods for the prevention and treatment of cerebral ischemia
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
US20140099262A1 (en) 2011-06-01 2014-04-10 Brain Watch Ltd. Isotopically labeled cdp-choline and uses thereof
PL2857037T3 (pl) 2012-05-31 2019-12-31 Kinki University Środek do leczenia profilaktycznego i/lub terapeutycznego obwodowego bólu neuropatycznego wywoływanego przez środek przeciwnowotworowy
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5517769B2 (cs) * 1972-01-10 1980-05-14
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
IT1207106B (it) * 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale
JPS6043078B2 (ja) * 1980-10-31 1985-09-26 株式会社興人 シチジンジリン酸コリンの製法
JPS57108099A (en) * 1980-12-25 1982-07-05 Kohjin Co Ltd Preparation of choline cytidine diphosphate
JPS6043079B2 (ja) * 1980-12-25 1985-09-26 株式会社興人 シチジン二リン酸コリンの製造方法

Also Published As

Publication number Publication date
US5872108A (en) 1999-02-16
US5801160A (en) 1998-09-01
IL147477A (en) 2010-02-17
KR19980702724A (ko) 1998-08-05
IN182555B (cs) 1999-05-01

Similar Documents

Publication Publication Date Title
DE69617692D1 (en) Bohr
EP0813365A4 (en) IMMUNOISOLATION
GB9526560D0 (en) Use of 2-Amino-Heterocycles
GB9503240D0 (en) Preparation
ZA961791B (en) Reduction of infarct volume using citicoline
IL117420A0 (en) Reduction of infarct volume using citicoline
PL321686A1 (en) Trensdermal preparation
IL116924A0 (en) Preparation of n-aryl- and n-hetarylhydroxylamines
ZA96725B (en) Use of phenyclyclohexylcarboxamides
GB9521028D0 (en) Monitors
GB2302809B (en) Antitumor agent
IL147477A0 (en) Reduction of infarct volume using citicoline
IL117786A (en) Preparation of alpha-bisoximes
ZA968873B (en) Isomerisation of equillin
GB9502673D0 (en) Combined shower
AU2002300446A1 (en) Reduction of infarct volume using citicoline
ZA965962B (en) Anti-piroplasmotic agent
IL118225A0 (en) Use of felodipine
GB2331014C (en) Therapeutic uses of glucan
GB9502637D0 (en) Reduction
TW318352U (en) Structure of bed-lifting (addition one)
IL115554A0 (en) Earthquake-proofing of structures
ZA962440B (en) Destressing of railtracks
IL117844A0 (en) Use of (s)-adenosyl-l-methionine
GB9514072D0 (en) Preparation of thionucleosides